Table 1

Subject characteristics (baseline)

Patients with MS
Healthy controls
(n=27)
All
(n=151)
Non-MSON
(n=71)
Unilateral MSON
(n=50)
Bilateral MSON
(n=30)
Sex (N, female)12 (44)99 (66)45 (63)34 (68)20 (67)
Age (years)52.2±5.453.8±9.656.1±9.051.3±9.252.2±10.6
Disease duration (years)N/A20.8±6.520.3±6.520.4±6.522.9±6.1
EDSS scoreN/A3.5 (3.0–5.0)3.5 (3.0–6.0)3.5 (2.5–5.0)4.0 (3.0–4.5)
Disease course
 Relapsing–remitting (N)N/A98 (65)42 (59)36 (72)20 (67)
 Secondary progressive (N)N/A34 (23)11 (32)14 (28)9 (30)
 Primary progressive (N)N/A19 (13)18 (25)0 (0)1 (3)
Current DMT use (N)N/A44 (29)16 (23)19 (38)9 (30)
mGCIPL mean ODS (μm)*92.1±6.277.2±14.082.6±12.672.8±12.470.7±15.4
  • Data are shown as mean±SD, median (IQR) or N (%).

  • *Baseline GCIPL ODS values available for 24 healthy controls and 118 patients with MS.

  • DMT, disease modifying treatment; EDSS, Expanded Disability Status Scale; mGCIPL, macular ganglion cell and inner plexiform layer; MS, multiple sclerosis; MSON, multiple sclerosis-associated optic neuritis; N, number; N/A, not applicable; ODS, left and right eye.